A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
Year: 2024
Type: article
Abstract: A randomized, double-blind study of zinpentraxin alfa in patients with
Source: Haematologica
Authors: Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, Alessandro Isidori, Peter Te Boekhorst, Michael R. Savona, Prithviraj Bose, Olga Pozdnyakova, Ruben Mesa, Tarec C. El-Galaly, Jennifer O’Sullivan, Katia Gamel, Brian Higgins, Sudhakar Katakam, Boyan Todorov, Kerstin Trunzer, Claire N. Harrison
Institutions: The University of Texas MD Anderson Cancer Center, University of Michigan, Michigan Medicine, Dana-Farber Cancer Institute, Erasmus MC, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Brigham and Women's Hospital, Harvard University, Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center, Aalborg University Hospital, Guy's and St Thomas' NHS Foundation Trust, F. Hoffmann-La Roche AG, Genentech
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funders: F. Hoffmann-La Roche, Galecto
OpenAlex ID: W4391228877